FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:1426-1429 March 30, 2006 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Drazen, J. M. Related Article by Haug, C. Related Article by Zarin, D. A. PubMed Citation

To the Editor: In the editorial, with Dr. Wood, on registration of clinical trials (Dec. 29 issue),¹ you unfairly criticize Pfizer and falsely claim that companies challenge the "spirit of the law." Pfizer's record is demonstrably excellent. Section 113 of the Food and Drug Administration Modernization Act (FDAMA 113) established ClinicalTrials.gov to help patients find clinical trials and new treatments for serious and life-threatening conditions. Pfizer has rigorously complied with the letter and the spirit of this law.

Your editorial concerned quite separate calls for greater transparency in registering new clinical studies. It failed to report the absence of agreed . . . [Full Text of this Article]

This article has been cited by other articles:

• Zarin, D. A., Ide, N. C., Tse, T., Harlan, W. R., West, J. C., Lindberg, D. A. B. (2007). Issues in the Registration of Clinical Trials. JAMA 297: 2112-2120 [Abstract] [Full Text]